Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
143.31
300.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Revenue
Alnylam Pharmaceuticals Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Revenue
$2.1B
|
CAGR 3-Years
41%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Alnylam Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Alnylam Pharmaceuticals Inc
Breakdown by Segments
Alnylam Pharmaceuticals Inc
|
Total Revenue:
1.8B
USD
|
|
Net Product Revenues:
1.2B
USD
|
|
Net Revenues From Collaborations:
546.2m
USD
|
|
Royalty Revenue:
40.6m
USD
|
Alnylam Pharmaceuticals Inc
Glance View
Alnylam Pharmaceuticals Inc. is at the forefront of transforming the landscape of genetic medicine through its pioneering work in RNA interference (RNAi) technology. Founded in 2002, the company embarked on a bold mission to develop innovative therapies for rare and challenging diseases caused by genetic mutations. By leveraging the power of RNAi, Alnylam enables the silencing of specific disease-causing genes, offering a potential cure rather than just symptomatic relief. Their flagship products, like Onpattro and GIVLAARI, have already gained approval for treating debilitating conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, making waves in the biotechnology sector and establishing the company as a leader in genetic medicines. Investors have taken note of Alnylam's unique position in a rapidly evolving market, propelled by its strong pipeline of therapies aimed at multiple diseases. With a robust clinical trial framework and strategic partnerships with major pharmaceutical players, Alnylam not only raises its profile but also enhances its growth potential. The company is on a path to deliver multiple additional product candidates and expand its therapeutic reach into areas like cardiometabolic and neurodegenerative diseases. For those looking to invest in a company that combines scientific innovation with robust market potential, Alnylam Pharmaceuticals represents a compelling narrative filled with promise and transformative possibilities in the realm of healthcare.
See Also
What is Alnylam Pharmaceuticals Inc's Revenue?
Revenue
2.1B
USD
Based on the financial report for Sep 30, 2024, Alnylam Pharmaceuticals Inc's Revenue amounts to 2.1B USD.
What is Alnylam Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
50%
Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Alnylam Pharmaceuticals Inc have been 41% over the past three years , 65% over the past five years , and 50% over the past ten years .
You don't have any saved screeners yet
